- Topic
44k Popularity
44k Popularity
28k Popularity
9k Popularity
19k Popularity
4k Popularity
32k Popularity
22k Popularity
34k Popularity
130k Popularity
- Pin
- 🎉 A Warm Welcome to Dr.Han on Gate Square!
Dr.Han — Founder of Gate and a seasoned crypto industry observer — is now officially sharing insights on Gate Square!
📢 Follow Dr.Han and like or comment on his latest post for a chance to win!
👉 Post: https://www.gate.com/post/status/11966645
👉 Profile: https://www.gate.com/profile/Dr_Han
🎁 Giveaway Alert:
We’ll randomly select 10 lucky users from those who follow + like/comment to receive a limited-edition Gate T-shirt — the same style worn by Dr.Han!
(If shipping is unavailable in your region, a $50 Futures Voucher will be provided instead.)
�
- 🔥 Gate Square #Gate Alpha Third Points Carnival# Trading Sharing Event is Live!
Share Alpha trading highlights screenshots with #Gate Alpha Trading Share# to split $100!
🎁 10 lucky users * 10 USDT each
📅 July 4, 4:00 – July 20, 16:00 UTC+8
Don’t forget—the main Alpha Points Carnival prize pool is up to $1,000,000!
Trade and post for double the chances to win!
Learn more: https://www.gate.com/announcements/article/45908
- 🎉 Gate xStocks Trading is Now Live! Spot, Futures, and Alpha Zone – All Open!
📝 Share your trading experience or screenshots on Gate Square to unlock $1,000 rewards!
🎁 5 top Square creators * $100 Futures Voucher
🎉 Share your post on X – Top 10 posts by views * extra $50
How to Participate:
1️⃣ Follow Gate_Square
2️⃣ Make an original post (at least 20 words) with #Gate xStocks Trading Share#
3️⃣ If you share on Twitter, submit post link here: https://www.gate.com/questionnaire/6854
Note: You may submit the form multiple times. More posts, higher chances to win!
📅 July 3, 7:00 – July 9,
- #GateSquareGiveaway# - Spot the Differences 👀
GM ☕ Our frog friend has two slightly different mornings—can you find all the changes?
💰 $10 Futures Voucher * 5 winners
To join:
🔹Follow Gate_Square
🔹Like this post and drop your answer in the comments
📅 Ends at 16:00 PM, July 7 (UTC)
Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.
On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter's inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.